- In February 2023, Yamo Pharmaceuticals announced Phase 3 trial results for its proprietary serotonin modulator aimed at treating core symptoms of autism.
- In May 2022, Curemark partnered with a U.S.-based research institute to scale up production of its enzyme-based therapy for pediatric autism.
- In 2024, Japan's Ministry of Health approved a new AI-assisted platform for autism diagnosis and medication management to improve early therapeutic interventions.
- The report also emphasized the rising trend of personalized medicine, microbiome-based therapies, and precision psychiatry. Increased focus on sustainable drug development and clinical validation of complementary treatments is accelerating the evolution of autism drug strategies.
